- Report
- February 2025
- 240 Pages
Global
From €2557EUR$2,690USD£2,148GBP
- Report
- January 2025
- 100 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- March 2025
- 92 Pages
Global
From €5324EUR$5,600USD£4,472GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- May 2024
- 137 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Drug Pipelines
- August 2024
- 150 Pages
Global
From €2651EUR$2,789USD£2,227GBP
- Report
- January 2024
- 395 Pages
Global
From €7130EUR$7,500USD£5,990GBP
- Report
- March 2024
- 200 Pages
Global
From €3945EUR$4,150USD£3,314GBP
- Report
- February 2024
- 227 Pages
China
From €3803EUR$4,000USD£3,195GBP
- Report
- February 2024
- 114 Pages
China
From €1711EUR$1,800USD£1,438GBP
- Report
- February 2024
- 82 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- March 2025
- 50 Pages
Global
From €2519EUR$2,650USD£2,116GBP
- Book
- July 2009
- 1116 Pages

Midazolam is a benzodiazepine drug used in the treatment of anxiety, insomnia, seizures, and sedation. It is a central nervous system (CNS) depressant, meaning it slows down the activity of the brain and nervous system. It is commonly used in medical settings for procedural sedation and as a premedication before surgery. Midazolam is also used to treat status epilepticus, a life-threatening condition characterized by prolonged seizures.
Midazolam is available in both oral and injectable forms, and is often used in combination with other drugs to achieve the desired effect. It is generally considered to be safe and effective when used as directed. However, it can cause side effects such as drowsiness, confusion, and respiratory depression.
Some companies in the Midazolam market include Pfizer, Mylan, Sandoz, and Teva Pharmaceuticals. Show Less Read more